Human Papillomavirus And Its Effects On Female Health

HPV is so common in the United States that nearly all men and women will contract the virus at some point during life (Center for Disease Control and Prevention [CDC], 2017). In the United States, in 2008, it is reported that 3.2 million, or one in four adolescent women, ages 14 to 19 have had or have an STD (Kostas-Polston et al., 2012). The rate of HPV cases has only increased since 2008. The prevalence of a genital infection with any HPV type was 42.5% among United States during 2013–2014 (CDC, 2017). The incidence of HPV in the United States is about 14 million people each year.

Human papillomavirus (HPV) is a killer. It is an awful disease that is the culprit of many deaths each year. We have the means for its prevention, yet HPV vaccination for girls is a controversial topic to some. This controversy carries over to the current question on whether or not males should also be vaccinated. The issue is starting to play a huge role in the media; Fox news recently broadcasted a story on male HPV vaccinations. This story makes clear the benefits that would come from vaccinating males, including a statement from the Center for Disease Control that, “The HPV vaccine will afford protection against certain HPV-related conditions and cancers in males, and vaccination of males with HPV may also provide indirect protection

Human papillomavirus is currently affecting the entire US population without discrimination. To mitigate this, the Advisory Committee on Immunization Practices (ACIP) recommended that adolescent girls be required to vaccinate at age 11 – 12 while boys were optional (Kepka et al., 2016). Today, adolescent boys are required to vaccinate too. The focus of this research is about adolescent boys age 12 – 15 in the United States (US). However, the study is not focused on assessing the population at risk. Instead, the focus will be on the state and territory immunization programs that are responsible for meeting the Healthy People 2020 goals for HPV vaccination in males. The sample size will be extracted from the population.

HPV is by far the most common sexually transmitted infection in the United States. Per the Centers for Disease Control and Prevention (CDC), 50 percent of all sexually active men and women will get it at some point in their lives, and 20 million already have it. A vaccine is available that prevents 70% of cervical cancers that arise from sexual intercourse. The human papillomavirus is unknowingly common and is diagnosed in 10,000 women a year, causing 4,000 deaths per year (“HPV Question and Answers”). If we take the responsibility to vaccinate young girls and boys, to be safe, we can eliminate many unnecessary deaths. This vaccine is a great discovery that should be put to good use, the HPV vaccine should be mandated in young teens everywhere.

The incidence of Human Papillomavirus (HPV) in my local community Lockport, Illinois is one out of every five people have HPV and due to the vaccinations to prevent HPV, Illinois ranks 48th among the United States for incidences of HPV (Manchir, 2013). HPV is a sexually transmitted infection that is transmitted through sexual contact. HPV is transmitted during vaginal, oral, or anal sex and on rare occasions, through birth during delivery (Illinois Department of Public Health [IDPH], 2013). Surprisingly, 50 percent of men and women that are active sexually will acquire HPV during their lifetime! HPV has affected 20 million Americans and an astounding, six million additional people will become infected every year (Illinois Department of Public Health [IDPH], 2013). Although Lockport Illinois has a lower amount of people with HPV, as a public health nurse, I realize this is an issue that needs to be addressed in my local community. Awareness is the key to prevention. Teenagers, parents, and all adults need to

Prophylactic vaccination against high risk human papilloma virus 16 and 18 represents an exciting means of protection against HPV related malignancy. However, this strategy alone, even if there is a level of cross protection against other oncogenic viruses, cannot completely prevent cervical cancer. In some countries cervical screening programs have reduced the incidence of invasive cervical cancer by up to 80 percent although this decline has now reached a plateau with current cancers occurring in patients who have failed to attend for screening or where the sensitivity of the tests have proved inadequate. Cervical screening is inevitably associated with significant anxiety for the many women who require investigation and treatment following abnormal cervical cytology. However, it is vitally important to stress the need for continued cervical screening to complement vaccination in order to optimize prevention in vaccines and prevent cervical cancer in older women where the value of vaccination is currently unclear. It is likely that vaccination will ultimately change the natural history of HPV disease by reducing the influence of the highly oncogenic types HPV 16 and 18. In the long term this is likely to lead to an increase in recommended screening intervals. HPV vaccination may also reduce

The authors appreciated the fact that Canada recently approved the use of the vaccine for males, which should decrease cervical, penile, and anal cancer rates and help in cost-savings. Unfortunately, the awareness of the new HPV vaccines remains low despite its efficacy and a small number of adverse

Human Papilloma Virus, more commonly known as HPV, is a sexually transmitted virus. It is spread from skin-to-skin contact with an infected person, typically during sexual encounters. It is the most common sexually transmitted disease in the United States. According to the Immunize Action Coalition, “most sexually active American men and woman will contract at least one type of HPV virus during their lifetime” (A Parent 's Guide to Preteen, 2013, p. 1). To put the numbers in perspective, it infects an estimated seventy-nine million Americans today with approximately fourteen million more people being affected additionally each year (Human

The Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI). There are over 100 types of HPV, but only 40 types affect the genital area and can cause genital warts and cervical cancer in women (“Human Papillomavirus (HPV) Vaccine”). In 2011 in the United States, 12,109 women were diagnosed with cervical cancer. Of those, 4,092 women died (“Cervical Cancer Statistics”). HPV is not only contracted from sexual intercourse, but also from skin to skin contact, including oral sex. The STI affects males and females involved in both homosexual and heterosexual sexual activities. Over 70 percent of sexually active individuals contract and carry HPV before the age of 80. In order to combat HPV two different brands of HPV vaccination – Gardasil and Cervarix – were created. Both include a vaccination plan of three shots over the course of six months. Gardasil was created by Merck & Co., and was licensed by the FDA in June 2006. The vaccine protects against HPV types 16 and 18, which lead to cervical cancer, as well as types 6 and 11, which cause 90% of genital warts. The FDA later approved Cervarix, created by GlaxoSmithKline, in 2009, which only protects against HPV types 16 and 18 (“Human Papillomavirus (HPV) Vaccine”). Originally, Gardasil was only approved for females, but three years after the release, the vaccine was approved

Did you know that most sexually-active men and women will get at least one type of HPV at some point in their lives. (CDC) The human papillomavirus, more commonly known as HPV, is a sexually transmitted infection. It is one of the most common sexually transmitted infections in the United States. HPV can be transmitted through vaginal, anal, or oral sex. The human papillomavirus can cause several types of cancers such as cervical cancers, anal cancer, oropharyngeal cancer, and others. The leading HPV vaccine, Gardasil, was licensed by the FDA is 2006. The second vaccine, Cervarix, came three years later. There are many views on the requirement of the HPV vaccine. The HPV vaccine should be required because it saves lives, is safe, and is effective.

Among the many arguments for mandatory HPV vaccination, the foremost is that it is an important medical achievement and a major public health milestone. This vaccine has proven to be one-hundred percent effective in preventing the 4 HPV strains that are responsible for seventy percent of cervical cancers and ninety percent of genital warts. In addition, no serious side effects have been identified. Because this vaccine is a preventive measure, administration before onset of sexual activity is ideal; however, even females who have been sexually active can still benefit from this vaccination (Perkins et al., 2010). Nationally and internationally, the HPV vaccine will significantly reduce disease burden by reducing monetary and psychological costs of invasive procedures that remove precancerous and cancerous lesions. By combining vaccination with routine Pap smear screening, these public health efforts have the remarkable opportunity to eradicate cervical cancer (Ramet et al., 2011).

Human Papilloma Virus (HPV) remains the most commonly sexually transmitted infection in both males and females. (Giuliano et al., 1999).

Human papillomavirus, commonly abbreviated as HPV, is the most common sexually transmitted virus that can cause a variety of diseases. It is transferred from person to person by either genital contact or from oral contact. Most men and women who are sexually active will be infected with this virus at least once in their life (“HPV”). A reason why HPV has become such a big problem in society is because of the fact that it is a virus, and thus cannot be treated with antibiotics. For other viral infections, it is possible to wait for the body’s immune system to rid the body of the foreign invader, but HPV is a virus that can cause more serious health problems such as genital warts, cancers of the mouth, anus, or vagina, as well as the cervix. Another reason why this problem exists in society may be due to more relaxed standards regarding sexual activity. In today’s society, people are more likely to have more than one sexual partner, making it easier for the virus to spread within the population. People are also becoming sexually active at younger ages before they receive education about safe sex at school or at home, which is also a factor in the spread of HPV in the population. Most people do not exhibit negative symptoms from the virus; indeed, some of them may not even know they have contracted it, for the body can clear out the virus on its own ninety percent of the time (“What is HPV?” 2013). HPV

Human papillomavirus (HPV) is a common sexually transmitted infection. HPV family of viruses comprises many oncogenic and non-oncogenic types that cause anal, penile, and oropharyngeal cancers and anogenital warts in men respectively. Men who have sex with men (MSM) are at particularly high risk for HPV infection and HPV-related disease (Markowitz et al., 2014). In one study, oncogenic HPV types 16 and/or 18 were detected in 37% of MSM between ages 16 and 30 years (Glick et al., 2014). Anal cancer rates are more than 17 times higher among MSM compared to their heterosexual counterpart (Daling et al., 2004, Joseph et al., 2008; Machalek et al., 2012). Anal cancer rates are even higher among HIV-positive MSM (Silverberg et al., 2012). Moreover, recent data revealed a rapid increase in HPV associated oropharyngeal cancers rates among men in the United States (Charturvedi et al., 2011). Aside from cancer, HPV associated anogenital warts negatively affect quality of life and are expensive to treat (Woodhall et al., 2011). Close to 7% of gay and bisexual men report a history of genital warts. (Dinh et al., 2008)

Most sexually active individuals will have detectable human papillomavirus (HPV) at least once in their lifetime. 14 million people are infected annually, and 79 million people have the prevalent infection. Approximate 5% of the cancers globally are HPV-associated anogenital or oral cancers (1). HPV is transmitted frequently between partners; more frequent transmission has been reported from females to males than from males to females (2). The incidence of anal and oral cancers related to HPV is increasing in the general population and is growing even faster among individuals who are immunocompromised because of human immunodeficiency virus (HIV) infection (3, 4). Two prophylactic vaccines (Gardasil and Cervarix) have been approved for a decade. Recently, the nonavalent vaccine including additional high-risk HPV types is promised to provide more coverage against cervical cancers (5). The HPV vaccine is recommended routinely for 11- or 12-year-olds, as well as for young men through age 21 years and young women through age 26 years who have not previously been vaccinated. HPV vaccine is also recommended for men who have sex with men (MSM), people living with HIV/AIDS, and immunocompromised persons through age 26 years. However, the high-risk HPV types included in the nonavalent vaccine contribute little to anal, oropharyngeal, penile, vulvar and vaginal cancer (5, 6).